The atopic dermatitis market is undergoing significant transformation as advances in immunology, increasing disease awareness, and the development of targeted therapies reshape the treatment landscape. Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by persistent itching, dryness, redness, and recurring flare-ups. The disease affects individuals across different age groups, with symptoms ranging from mild irritation to severe inflammation that can interfere with sleep, daily activities, and overall quality of life.